- Home
- NNNN vs DBL Comparison
NNNN vs DBL Comparison
Compare NNNN & DBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNNN
- DBL
- Stock Information
- Founded
- NNNN 2021
- DBL 2011
- Country
- NNNN Germany
- DBL United States
- Employees
- NNNN N/A
- DBL N/A
- Industry
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- DBL
- Sector
- NNNN Health Care
- DBL
- Exchange
- NNNN Nasdaq
- DBL Nasdaq
- Market Cap
- NNNN 369.6M
- DBL 296.0M
- IPO Year
- NNNN 2025
- DBL N/A
- Fundamental
- Price
- NNNN $49.26
- DBL $15.30
- Analyst Decision
- NNNN
- DBL
- Analyst Count
- NNNN 0
- DBL 0
- Target Price
- NNNN N/A
- DBL N/A
- AVG Volume (30 Days)
- NNNN 220.1K
- DBL 61.0K
- Earning Date
- NNNN 01-01-0001
- DBL 01-01-0001
- Dividend Yield
- NNNN N/A
- DBL 8.67%
- EPS Growth
- NNNN N/A
- DBL N/A
- EPS
- NNNN 0.06
- DBL N/A
- Revenue
- NNNN $8,185,146.00
- DBL N/A
- Revenue This Year
- NNNN N/A
- DBL N/A
- Revenue Next Year
- NNNN N/A
- DBL N/A
- P/E Ratio
- NNNN $908.77
- DBL N/A
- Revenue Growth
- NNNN 21.95
- DBL N/A
- 52 Week Low
- NNNN $5.18
- DBL $13.75
- 52 Week High
- NNNN $53.11
- DBL $15.70
- Technical
- Relative Strength Index (RSI)
- NNNN N/A
- DBL 39.43
- Support Level
- NNNN N/A
- DBL $15.27
- Resistance Level
- NNNN N/A
- DBL $15.37
- Average True Range (ATR)
- NNNN 0.00
- DBL 0.10
- MACD
- NNNN 0.00
- DBL -0.02
- Stochastic Oscillator
- NNNN 0.00
- DBL 14.29
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.